REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of Two Nitrogens And Four Carbon Atoms (e.g., Pyridazines, Etc.) > 1,4-diazine As One Of The Cyclos > Additional Hetero Ring Attached Directly Or Indirectly To The 1,4-diazine Ring By Nonionic Bonding Additional Hetero Ring Attached Directly Or Indirectly To The 1,4-diazine Ring By Nonionic BondingAdditional Hetero Ring Attached Directly Or Indirectly To The 1,4-diazine Ring By Nonionic Bonding patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/25/07 - 20070021440 - Inhibitors of macrophage migration inhibitory factor and methods for identifying the same including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same. ... 01/25/07 - 20070021439 - Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers Prophylactic treatment methods are provided for protection of individuals and/or populations against infection from airborne pathogens. In particular, prophylactic treatment methods are provided comprising administering a sodium channel blocker or pharmaceutically acceptable salts thereof to one or more members of a population at risk of exposure to or already exposed ... 01/11/07 - 20070010531 - Substituted pyrazole compounds Compounds of the formula (I) and salts and solvates thereof, in which X, R1, R2, R3, and R5 have the meanings indicated in claim 1, are suitable as ligands of 5 HT receptors. ... 12/28/06 - 20060293341 - Alkyl sulfonamide derivatives This invention is directed to alkyl sulfonamide derivatives which are ligands at the NPY Y5 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically ... 12/28/06 - 20060293340 - 2-aminopyrimidine derivatives as raf kinase inhibitors This application discloses compounds that inhibit Raf kinase having the formula (I), wherein R1 is a phenyl radical or a heteroaryl radical; and R2 is a phenyl radical; or an N-oxide or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of proliferative diseases, such as cancer. ... 12/28/06 - 20060293339 - Biaryl substituted 6-membered heterocycles as sodium channel blockers Biaryl substituted pyridine, pyrimidine and pyrazine compounds are sodium channel blockers useful for the treatment of pain. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, ... 12/21/06 - 20060287339 - Aza- and polyazanthranyl amides and their use as medicaments Aza- and polyazanthranyl amides and their use as medicaments in the treatment of diseases caused by persistent angiogenesis are described, as well as the intermediates used in the preparation of the aza- and polyazanthranyl amides. ... 12/14/06 - 20060281761 - 4-azasteroid derivatives as androgen receptor modulators Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. ... 12/14/06 - 20060281760 - Tubulin inhibitor and process for its preparation The invention provides 6-chloro-5-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-2-pyrazin-2-yl-N-[(1S)-2,2,2-trifluoro-1-methylethyl]pyrimidin-4-amine hemifumarate which is a tubulin inhibitor useful in the treatment of cancer and processes of making said hemifumarate. ... 11/30/06 - 20060270687 - Kinase inhibitors or pharmaceutically acceptable salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating protein kinase-associated disease states using the compound of formula I is also described. ... 11/30/06 - 20060270686 - Anti-cancer agents and uses thereof and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3—R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring ... 11/23/06 - 20060264444 - Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases The present invention relates to substituted indoles of formula (I) useful as pharmaceutical compounds for treating respiratory disorders. ... 10/19/06 - 20060235028 - Inhibitors of 11-beta hydroxysteroid dehydrogenase type i or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein G, L, Q, Z, R6, R7, and R8 are defined herein. ... 10/05/06 - 20060223832 - Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds. ... 10/05/06 - 20060223831 - Bromide and its crystal The 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide of the invention and its crystals, particularly α- and β- form Crystals, have no hygroscopic property, have excellent stability and therefore are useful as production materials of medicines. Particularly, the β- form Crystal is most stable and markedly useful as a bulk for medicines. ... 09/21/06 - 20060211710 - Substituted aryl 1,4-pyrazine derivatives The invention is directed to compounds of Formula I, described herein, as well as pharmaceutically acceptable salts thereof, which act as CRF1 antagonists and are useful in the treatment of disorders and diseases associated with CRF1 receptors, including CNS-related disorders and diseases. ... 09/21/06 - 20060211709 - Protein kinase modulators and methods of use Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed. ... 09/14/06 - 20060205739 - Aroylfuranes and aroylthiophenes The invention relates to novel substituted 2-(phenyl-, pyridyl- or pyrimidyl-carbonyl)-furanes and -thiophenes and related phenoxy/phenylthio-acetophenones and corresponding heterocyclic compounds, processes for the preparation thereof, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of neoplastic diseases and autoimmune ... 09/14/06 - 20060205738 - Capped pyrazinoylguanidine sodium channel blockers The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers. ... 09/07/06 - 20060199828 - Pyrazine-2-carboxyamide derivatives wherein R1, R2 and R3 are as defined in the specification. These compounds are useful for the treatment of CNS disorders. ... 08/31/06 - 20060194818 - Inhibitors of macrophage migration inhibitory factor and methods for identifying the same including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same. ... 08/17/06 - 20060183752 - Process for preparing 2, 3-disubstituted indoles a) reacting a bromoindole compound (i) with a dialkoxyl C1-5 borane in the presence of a ligand, a palladium catalyst and a base to make a compound of general formula (ii); or alternatively reacting compound (i) with a trialkyl magnesiate reagent, followed by treatment with a borate; b) reacting the ... 08/10/06 - 20060178374 - Aminoheteroaryl compounds as protein kinase inhibitors Aminoheteroaryl compounds are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers. ... 08/03/06 - 20060173021 - Compounds for inflammation and immune-related uses or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein R, R1, R2, Z, L, and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders. ... 08/03/06 - 20060173020 - 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives The 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I) possess cell cycle inhibitory activity and are accordingly useful for their anti cell proliferation (such as anti cancer) activity. ... // - 1,2,4-Triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I), pharmaceutically acceptable salts thereof, processes for the manufacture of 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives and pharmaceutical compositions containing 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives are disclosed: - ... 07/27/06 - 20060167015 - Inhibitors of tyrosine kinases wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy ... 07/06/06 - 20060148823 - Tricyclic delta-opioid modulators The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described. ... 07/06/06 - 20060148822 - 5-phenylthiazole derivatives and their use as p13 kinase inhibitors in free or salt form, wherein R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. ... 06/29/06 - 20060142307 - Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions Methods for using aminopyrazine analogs to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of ... 06/29/06 - 20060142306 - Sodium channel blockers The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers. ... 06/22/06 - 20060135535 - Phosphodiesterase 4 inhibitors wherein R1, R2, and R3 are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof. ... 06/22/06 - 20060135534 - Pyrazine based inhibitors of glycogen synthase kinase 3 New bicyclic based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in ... 06/15/06 - 20060128724 - Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers. ... 06/15/06 - 20060128723 - Sulptionamide compounds that modulate chemokine receptor activity (ccr4) The invention provides thienylsulphonamides for use in therapy. ... 06/15/06 - 20060128722 - Indoles useful in the treatment of androgen-receptor related diseases or a salt or hydrate form thereof. ... 06/08/06 - 20060122195 - Sulphonamide compounds that modulate chemokine receptor activity (ccr4) The invention relates to sulphonamide compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy. ... 06/01/06 - 20060116385 - Novel compounds having selective inhibiting effect at gsk3 The present invention relates to new compounds of formula (I) wherein Z is N; Y is CONR5, NR5CO, SO2NR5, NR5SO2, CH2NR5, NR5, NR5CONR5, CH2CO, CO, O or CH2O; X is CH or N; P is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms selected ... 05/25/06 - 20060111370 - Heterocyclic aspartyl protease inhibitors Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist. ... 05/04/06 - 20060094729 - N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described. ... 04/27/06 - 20060089370 - Thieno-pyrimidine compounds having fungicidal activity The present invention relates to thieno[2,3-d]-pyrimidine compounds having fungicidal activity. ... 04/27/06 - 20060089369 - Inhibitors of glycogen synthase kinase 3 New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active ... 04/20/06 - 20060084663 - Peroxisome proliferator activated receptor modulators The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I: wherein: (a) R5 is selected from the group consisting of (C1-C6) alkyl, (C1-C6) alkenyl, substituted aryl(C0-C4)alkyl, substituted aryloxy(C0-C4)alkyl, substituted arylthio(C0-C4)alkyl, unsubstituted aryl(C0-C4)alkyl, unsubstituted aryloxy(C0-C4)alkyl, and unsubstituted arylthio(C0-C4)alkyl; (b) T1 is ... 03/23/06 - 20060063781 - Pharmaceutical composition for regeneration of cirrhotic liver The present invention provides a pharmaceutical composition and the use thereof for regeneration of liver tissues to treat cirrhotic liver, the composition including 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) as an active ingredient. The oltipraz composition promotes regeneration of liver tissues in a cirrhotic liver, thereby useful in treating cirrhosis. ... 03/23/06 - 20060063780 - Sodium channel blockers The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers. ... 03/23/06 - 20060063779 - Pyridyl inhibitors of hedgehog signalling wherein A, X, Y R1, R2, R3, R4, m and n are as described herein. ... 03/16/06 - 20060058315 - 2-oxo-ethanesulfonamide derivates Compounds of formula (I): Formula (I) wherein variable groups are as defined within; for use in the inhibition of 11βHSD1 are described. ... 03/09/06 - 20060052395 - Capped pyrazinoylguanidine sodium channel blockers The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers. ... 03/09/06 - 20060052394 - Capped pyrazinoylguanidine sodium channel blockers The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers. ... 02/23/06 - 20060040954 - Soluble amide & ester pyrazinoylguanidine sodium channel blockers The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers. ... 01/12/06 - 20060009472 - Substituted imidazole derivatives The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula: ... 12/01/05 - 20050267130 - Tetrahydrocarboline antiviral agents The invention encompasses a series of tetrahydrocarboline compounds of Formula I which inhibit HIV entry by attaching to the exterior viral envelop protein gp120 and interrupting the viral entry process, possibly by interfering with the cellular receptor CD4. This action makes the compounds useful for treating HIV infection and AIDS. ... 11/17/05 - 20050256135 - Tetrahydronaphthyridine derivatives in which A and R1 are as defined within, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, including the treatment diseases mediated by H3 ligands, in particular inflammatory, allergic and respiratory diseases, disorders and conditions. ... 11/03/05 - 20050245542 - Pyridazine, pyrimidine and pyrazine ethyne compounds In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted or unsubstituted six membered heterocyclic ring that includes at least two nitrogen atoms. The ring additionally includes four carbon atoms. The heterocyclic ring has at least one substituent ... 10/27/05 - 20050239801 - Novel compounds The invention provides compounds of general formula (I) wherein m, n, Z1, Z2, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the specification, process for their preparation, pharmaceutical compositions containing them and their use in therapy. ... 10/27/05 - 20050239800 - Polycyclic pyrazines as potassium ion channel modulators The present invention provides a genus of polycyclic pyrazines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods. ... 10/20/05 - 20050234072 - Capped pyrazinoylguanidine sodium channel blockers The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers. ... 10/13/05 - 20050228000 - Bicyclic heterocycles useful as serine protease inhibitors or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, L1, L2, X1, X2, X3, X4, X5, R4, and W are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact ... 09/01/05 - 20050192291 - N-ureidoalkyl-piperidines as modulators of chemokine receptor activity or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases. ... 08/11/05 - 20050176733 - Chk-1 inhibitors This invention provides compounds and methods for treating cancer. More particularly, the invention provides compounds that inhibit Chk-1. These compounds potentiate the action of DNA-damaging agents such as chemotherapy and radiation therapy. ... 07/14/05 - 20050153985 - Methods of treating acute inflammation in animals with p38 map kinase inhibitors The present invention provides methods for treating animals having acute inflammatory conditions, including mastitis, by administering at least one p38 MAP kinase inhibitor. The present invention also provides methods for enhancing milk production and reducing milk discard in animals afflicted with acute inflammatory conditions by administering at least one, p38 ... 07/14/05 - 20050153984 - Vanilloid receptor ligands and their use in treatments and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic ... 07/07/05 - 20050148599 - Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to ... ### FreshPatents.com Support |